Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment
Diabetic Medicine · 2023-04 · 40 (4)
DOI: 10.1111/dme.15053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, online erschienen am 06.02.2023. Verfasst von Kaenat Mulla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Beta Cell Diabetes Unit, Chelsea and Westminster Hospital, London, UK. Hauptthemen laut MEDLINE: Hyperglycemia, Diabetes Mellitus, Type 1, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Aims
We systematically studied the presence of hyperglycaemia during treatment with Immune Checkpoint Inhibitors (ICPI) for cancer, in those with and without diabetes at baseline, and determined the cause of new‐onset hyperglycaemia, Methods Retrospective review of electronic records of those receiving an ICPI for melanoma, lung or renal cancer.
Results
Overall, 959 participants were included. In this study, 103 had diabetes at baseline (10.7%). Those with lung cancer had the highest frequency of diabetes; 131 people had hyperglycaemia (defined as at least one glucose ≥11.1 mmol/L) in the year after starting an ICPI. The incidence was 55% in those with diabetes at baseline, and 8.6% in those without baseline diabetes. Among 74 with new‐onset hyperglycaemia (without pre‐existing diabetes) 76% was attributable to steroid induced diabetes, with 9.5% due to ICPI Induced diabetes resembling type 1 diabetes.
Conclusions
Hyperglycaemia is common in persons receiving an ICPI for cancer, including 8.6% of those without known diabetes. While much of this is due to glucocorticoid use, care is needed to avoid missing those with ICPI‐induced diabetes who are at risk of diabetic ketoacidosis, which is a medical emergency.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Beta Cell Diabetes Unit, Chelsea and Westminster Hospital, London, UK.
- Skin Unit, Royal Marsden Hospital, London, UK.
- Data Unit, Royal Marsden Hospital, London, UK.
- Lung Unit, Royal Marsden Hospital, London, UK.
ORCID-Profile: Daniel Laurence Morganstein
Zitieren
APA
Mulla, K., Farag, S., Moore, B., Matharu, S., Young, K., Larkin, J., Popat, S., & Morganstein, D. L. (2023). Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabetic Medicine, 40(4). https://doi.org/10.1111/dme.15053
Vancouver
Mulla K, Farag S, Moore B, Matharu S, Young K, Larkin J, et al. Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabetic Medicine. 2023;40(4). doi:10.1111/dme.15053
BibTeX
@article{Mulla2023,
author = {Mulla, Kaenat and Farag, Sheima and Moore, Benedict and Matharu, Sheila and Young, Kate and Larkin, James and Popat, Sanjay and Morganstein, Daniel Laurence},
title = {Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment},
journal = {Diabetic Medicine},
year = {2023},
volume = {40},
number = {4},
doi = {10.1111/dme.15053}
}
EUVIMED